

## The Bureau of Justice Assistance Prescription Drug Monitoring Program at a Glance

In the field, BJA's resources in the area of Prescription Drug Monitoring Programs (PDMPs) serve several critical functions:

- Provide resources for data collection and analysis systems at the state level;
- Provide enhancements funding for existing programs; and
- Facilitate the exchange of collected prescription data among state and local authorities (e.g. law enforcement, occupational licensing boards, certification and regulatory personnel, pharmacists, and physicians).

State	Agency Housing the PDMP	Schedules of Drugs Monitored	Federal Award Amounts					PDMP State and Local Contact	
			FY02	FY03	FY04	FY05	FY06		FY07
Alabama	Department of Public Health	II, III, IV, V		\$300,000	\$350,000	\$350,000	\$400,000	\$400,000	Patti Stadlberger, (334) 206-7981
Alaska	Division of Corporations, Business and Professional Licensing	**						\$49,436	Brian Howes, (907) 269-8109
Arizona	Board of Pharmacy	II, III, IV				\$50,000		\$50,000	Hal Wand, (623) 463-2727
California	Department of Justice, Bureau of Narcotic Enforcement	II,III, IV		\$887,745		\$350,000	\$400,000	\$400,000	Katherine Ellis, (916) 319-8463
Colorado	Department of Regulatory Agencies	II, III, IV, V			\$50,000		\$400,000		Wendy Anderson, (303) 894-7754
Connecticut	Department of Consumer Protection	II, III, IV, V			\$50,000		\$400,000	\$314,206	John Gadea, (860) 713-6065
Florida	Florida Office of Drug Control	**		\$300,000	\$350,000				Bill Janes, (850) 488-9557
Hawaii	Hawaii Department of Public Safety	II, III, IV			\$349,530	\$349,954		\$400,000	Glen Kimura, (808) 837-8481
Idaho	Board of Pharmacy	II, III, IV		\$97,320			\$191,302		Mark Johnston, (208) 334-2356
Illinois	Department of Health and Human Services	II, III, IV, V				\$349,994	\$400,000	\$400,000	Stanley Tylman, (217) 524-9074
Indiana	Indiana Professional Licensing Agency	II, III, IV, V			\$281,876	\$216,796	\$373,659	\$389,312	Marty Allain, (317) 234-2067
Iowa	Department of Public Health	II, III, IV			\$350,000	\$292,963			Terry Witowski, (515) 281-5944
Kansas	Board of Pharmacy	**			\$50,000				Debra Billingsley, (785) 296-4056
Kentucky	Cabinet for Health & Family Services, Office of the Inspector General	II, III, IV, V		\$240,000	\$350,000	\$350,000	\$400,000	\$400,000	Dave Hopkins, (502) 564-7985
Louisiana	Board of Pharmacy	Schedules monitored to be determined				\$50,000	\$400,000		Malcolm Broussard, (225) 925-6481
Maine	Office of Substance Abuse	II, III, IV		\$300,000	\$109,650	\$339,164	\$285,950		Daniel Eccher, (207) 287-3363
Massachusetts	Massachusetts Department of Public Health	II		\$219,998	\$350,000	\$350,000		\$400,000	Grant Carrow, (617) 983-6701
Michigan	Bureau of Health Professions	II, III, IV, V				\$350,000			Michael Wissel, (517) 335-1769
Minnesota	Board of Pharmacy	II, III							Cody Wiberg, (651) 201-2825
Mississippi	Board of Pharmacy	II, III, IV, V			\$349,915	\$350,000	\$400,000		Mac McDivitt, (601) 605-5388
Missouri	Department of Health and Senior Services	**				\$50,000			Susan McCann, (573) 751-6321
Montana	Montana Board of Crime Control	**						\$50,000	Lily Yamamoto, (406) 444-1610
Nevada	Board of Pharmacy	II, III, IV		\$515,267	\$344,581	\$340,298		\$400,000	Larry Pinson, (775) 850-1440
New Hampshire	Department of Justice	**				\$49,836			Dave Strang, (603) 271-1246
New Jersey	Department of Law and Public Safety	**			\$350,000				Eric Rosen, (973) 504-6584
New Mexico	Board of Pharmacy	II, III, IV		\$245,650					Bill Harvey, (505) 222-9130
New York	New York Bureau of Narcotic Enforcement	II, III, IV, V		\$300,000	\$350,000	\$350,000	\$400,000	\$400,000	James Giglio, (518) 402-0707
North Carolina	Department of Health and Human Services	II, III, IV, V			\$50,000		\$399,900		John Womble, (919) 715-2771
North Dakota	Board of Pharmacy	Schedules monitored to be determined					\$372,315		Howard Anderson, (701) 328-9535
Ohio	Board of Pharmacy	II, III, IV, V		\$180,000		\$350,000	\$400,000	\$400,000	Danna Droz, (614) 466-4143
Oklahoma	Bureau of Narcotics and Dangerous Drugs	II, III, IV, V			\$350,000	\$350,000	\$259,820	\$400,000	John Duncan, (405) 521-2885
Oregon	Board of Pharmacy	**			\$350,000				Gary Schnabel, (503) 731-4032
Pennsylvania	Office of Attorney General	II		\$180,000	\$350,000				Lawrence Cherba, (610) 791-6145
Rhode Island	Board of Pharmacy	II, III							Catherine Cordy, (401) 222-2837
South Carolina	Department of Health and Environmental Control	II, III, IV			\$350,000				Wilbur Harling, (803) 896-0636
Tennessee	Board of Pharmacy	II, III, IV, V			\$50,000	\$350,000		\$143,459	Kolleen Matthews, (615) 253-1305
Texas	Department of Public Safety	II, III, IV, V					\$349,010	\$375,427	Kelli Cox, (512) 424-2189
Utah	Department of Commerce, Division of Occupational & Provisional Licensing	II, III, IV, V		\$80,005					Marvin Sims, (801) 530-6232
Vermont	Department of Health	II, III, IV				\$350,000		\$398,388	Barbara Cimaglio, (802) 651-1550
Virginia	Board of Pharmacy	II, III, IV		\$180,000	\$82,300	\$350,000	\$400,000	\$400,000	Ralph Orr, (804) 662-9921
Washington	Disciplinary Board	Determined by disciplinary authority			\$50,000				Donald Williams, (360) 236-4825
West Virginia	Board of Pharmacy	II, III, IV		\$180,000	\$350,000				William Douglass, (304) 558-0558
Wyoming	Board of Pharmacy	II, III, IV			\$214,529				James Carder, (307) 234-0294

\*\*These states do not currently have legislation or regulation to establish a PDMP in place.

**PLEASE NOTE:**

Washington currently has a triplicate prescription form program. The program applies to licensed practitioners and is used for disciplinary purposes or for disciplinary board supervision of a practitioner's practice.

A Prescription Drug Monitoring Program is defined as a program that is currently collecting prescription data and can respond to requests for reports by those authorized to make these requests (*The National Alliance for Model State Drug Laws, 2007*).

Schedules of Drugs Monitored: A list of controlled substances which identify how the substances on each list can be prescribed, dispensed or administered. A substance is placed on a particular schedule after consideration of several factors, including the substance's accepted medical usage in the United States and potential for causing psychological or physical dependence.

The information in this chart is current as of November 6, 2007.

Developed with the National Alliance for Model State Drug Laws under cooperative agreement 2005-PM-BX-K014 awarded by the Bureau of Justice Assistance, Office of Justice Programs, U.S. Department of Justice.